Pathos AI, a Chicago biotech led by executives of the healthcare AI group Tempus, is looking at a funding round of up to $400 ...

When it comes to shares of Tempus AI (NASDAQ: TEM), many may feel like they're standing on a dock watching the stock sail off ...

By 2030, we won't be asking AI what the data says. I believe we'll be asking it what we should create next. The creative ...

Tempus AI has announced that it is using the TIME Network to support Phase I trials and expedite site activation and ...

The rate of surgical overtreatment of low-risk prostate cancer showed a significant decline between 2010 and 2024, reflecting ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, is leveraging its TIME Network to expand its support in phase I clinical ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced Tempus Loop, a new oncology-focused platform for target ...

We recently published a list of Why These 10 Firms Recorded Double-Digit Gains Last Week. In this article, we are going to ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $63.78, ...

Tempus AI (TEM) has seen a significant surge on Wednesday, with its stock climbing 14.62% in just one day. The significant boost in TEM stock ...

With the stock market in rally mode, there are more pockets of strength than there have been in a while. Among the winners ...

Tempus AI CEO Eric Lefkofsky, Netflix Co-CEO Ted Sarandos and Dutch Bros Chairman Travis Boersma. Correction: An earlier version of this story misstated the role that Travis Boersma holds at Dutch ...